뉴스벤징가
Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications
· 발표
기사 요약
FDA warns of risks from unapproved compounded GLP-1 drugs including semaglutide and tirzepatide amid rising adverse event reports.
기사 원문에서 발췌했어요.FDA warns of risks from unapproved compounded GLP-1 drugs including semaglutide and tirzepatide amid rising adverse event reports.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…